Telix Pharmaceuticals Limited (ASX:TLX)
13.24
-0.16 (-1.16%)
Nov 17, 2026, 11:35 AM AEDT
Telix Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 12 analysts polled by S&P Global, Telix Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $24.17. The average 1-year stock price forecast is 82.62% higher than the current stock price, while the lowest is $18.80 (+42.05%) and the highest is $31.50 (+138.01%).
Price Target: $24.17 (+82.62%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Telix Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 9 | 8 | 8 | 6 | 6 |
| Buy | 6 | 5 | 4 | 4 | 4 | 5 |
| Hold | 0 | 1 | 3 | 1 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 15 | 15 | 13 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $31.50 | Buy | Maintains | $31.50 | +138.01% | Nov 8, 2026 |
| Jarden | Jarden | Buy Maintains $21.00 | Buy | Maintains | $21.00 | +58.67% | Nov 6, 2026 |
| Citi | Citi | Buy Maintains $31.00 | Buy | Maintains | $31.00 | +134.23% | Nov 4, 2026 |
| UBS | UBS | Buy Maintains $26.00 | Buy | Maintains | $26.00 | +96.45% | Nov 4, 2026 |
Unknown Analyst Ord Minnett No rating | Ord Minnett | Buy Maintains $22.00 → $18.80 | Buy | Maintains | $22.00 → $18.80 | +42.05% | Oct 27, 2026 |
Financial Forecast
Revenue This Year
939.09M
from 803.79M
Increased by 16.83%
Revenue Next Year
1.07B
from 939.09M
Increased by 13.81%
EPS This Year
0.05
from -0.02
EPS Next Year
-0.01
from 0.05
EPS and Forward PE are based on non-GAAP adjusted numbers.